This invention introduces a novel cell secretome protein composition derived from bone marrow and peripheral blood progenitor cells grown on an Electrospun Nano-fiber Scaffold (ENS). The secretome is designed as a one-step harvest and delivery system for direct application to wounds, which can be used in both bandage and salve forms.
Figure (1) SEM images for cell Secretome (hereinafter referred to as CS1) and Cell Secretome 2 (hereinafter referred to as CS2) (day 4) at magnifications 2000, 3000 and 5000X showing matrix fibres glued to one another due to presence of CS1 (A,B and C) and cells adhering to ENS fibers along with cell secretome entrapment (D,E and F); (2) Wound healing response in Diabetic mice when treated with CS1 and CS2 from days 0 to 10, CS1 and CS2 are both beneficial in treatment of diabetic wounds. CS2 is significantly more efficacious in diabetes wound healing than CS1
Managing wounds that heal slowly or improperly, particularly in diabetic patients or those recovering from burns and surgeries, poses significant healthcare challenges. These wounds can lead to complications like severe scarring and amputations. Current treatments often inadequately promote healing, highlighting the need for more effective and easy-to-apply solutions that can expedite recovery and reduce scarring in clinical and emergency settings.
- Electrospun Nano-fiber Scaffold: Utilizes a novel ENS to grow progenitor cells, enhancing their ability to produce beneficial secretomes.
- Combined Harvest and Delivery System: Simplifies the traditional complex processes of collecting and applying therapeutic proteins, allowing immediate, direct application to wounds.
- Cryopreservation Compatibility: Ensures long-term storage and readiness of the therapeutic bandage, enhancing its practical use in both clinical and emergency settings.
The prototype involves an ENS loaded with progenitor cells that produce a cell secretome, capable of direct application to wound sites. Early testing has shown that this system can significantly enhance wound healing and reduce scarring, confirming its efficacy and potential for commercial development.
The technology is currently in the prototype stage and has shown promising results in initial laboratory and animal model tests, demonstrating effectiveness in enhancing wound healing and reducing scarring. It is now poised for further clinical trials to validate its safety and efficacy for potential medical and veterinary use.
4
This technology has the potential to significantly improve quality of life by reducing the physical and psychological burden of wound care. It could lower healthcare costs through reduced treatment times and improved healing outcomes, particularly in chronic wound management and emergency care settings.
- Medical and Veterinary Care: Useful in treating a variety of wounds including diabetic ulcers, burns, and surgical incisions across human and veterinary medicine.
- Research and Pharmaceutical Industries: Offers a platform for developing new wound care products and therapeutic strategies.
Geography of IP
Type of IP
1951/MUM/2014
419521